contained 4,001 full genome sequences of infl uenza viruses isolated from humans, 2,590 of viruses isolated from birds, and only 325 from swine, 85 from horses, 2 from mink, 4 from dogs, 2 from cats, 2 from tigers, and 3 from seals.
We invite donors and international agencies to invest in a novel approach to infl uenza virus infections, to abandon prefi xed compartments linked to geographic origin or species of isolation, and to analyze the infl uenza gene pool as one entity. We propose capitalizing on existing achievements and investments to develop an international network and a permanent observatory, which will improve our understanding of the dynamics of the infl uenza virus gene pool in animals and humans. A greater understanding will generate important information to support both public and animal health. Ideally, a small consortium, including representatives of major international organizations, could take leadership and liaise with major institutions involved in infl uenza surveillance and research to develop a feasibility study and roadmap to achieve this goal. The One Flu initiative could result in international synergies, the bridging of gaps between medical and veterinary scientists, permanent monitoring of virus evolution and epidemiology, and the best exploitation of investments in capacity building. Above all, this collaboration could be a challenge and opportunity to implement the One Health vision, and possibly act as a model for other emerging zoonotic diseases. Of the 422 nurses included in the analysis, 42 (10.0%) showed seroconversion to pandemic (H1N1) 2009. Of 128 nurses who received the trivalent infl uenza vaccine, 9 (7.0%) showed seroconversion vs. 33 (11.2%) of those that did not (relative risk 0.63, 95% confi dence interval 0.31-1.27, p = 0.19).
Ilaria Capua and Giovanni Cattoli
Although the point estimate was protective, the confi dence interval is wide and does not exclude an increase in risk. Our sample size limits inferences that can be drawn. Heterotypic antibodies may have contributed to the relatively high rate of seroconversion. A rise in antibody titer is considered by some as an outcome associated with bias, unlike virus identifi cation. Nevertheless, these data suggest a possible positive effect of seasonal infl uenza vaccine reducing risk of infection with pandemic (H1N1) 2009. Follow-up is maintained by daily phone conversations with medical staff until disease outcome is concluded by discharge, transfer to a long-term rehabilitation facility, or death. Medical records, as well as daily laboratory reports, are collected to confi rm or to rule out pandemic (H1N1) 2009 infection.
During July 10-October 10, 2009, our prospective cohort included 17 patients with pandemic (H1N1) 2009 laboratory-confi rmed infection who were residents of the district; 12 (70.6%) were male patients. The median age was 44 years (interquartile range 13-72 years). By October 10, 2009, six patients had been discharged, 7 had died, 2 had been transferred to long-term rehabilitation facilities, and 2 remained hospitalized.
Twelve (70.6%) patients had an underlying medical condition, mainly chronic lung disease (6 patients) or chronic cardiovascular disease (5 patients). Two patients were morbidly obese (body mass index >35), and 1 patient was pregnant. Additionally, 3 patients (17.6%) were infected while hospitalized.
Thirteen patients (76.5%) had acute respiratory distress syndrome caused by diffuse viral pneumonitis. Other notable manifestations were acute renal failure (6 patients), sepsis/ septic shock (5 patients), and neurologic complications such as GuillainBarré syndrome, encephalitis, and seizures (3 patients).
Documented nosocomial sepsis, often of multiple gram-negative bacteria (9 patients), was the most frequent complication during the course of the disease. Other frequent characteristics were the use of high positive end-expiratory pressure during mechanical ventilation (4 patients) and the need for tracheostomy (5 patients).
Average time from disease onset to hospital admission was 3 days. Time from hospital admission to ICU admission for those patients who died was longer than for those who survived, with a median of 2 days compared with 0.5 day, respectively, albeit not signifi cant (p = 0.26). Average hospitalization was 23.4 days; average length of stay in the ICU was 16.7 days (71.4% of the average hospitalization time).
As mentioned previously, 7 patients (41.2%) died; 5 (71.4%) were male, similar to their cohort's proportion. One signifi cant difference (p = 0.02) was found between the age of survivors (mean 26.0 years, 95% confi dence interval 7.6-44.3) and the age of nonsurvivors (mean 59.3 years, 95% confi dence interval 39.6-79.0). The most prominent case-fatality rate was for elderly patients, >65 years of age (3 of 4 patients) followed by patients between 20 and 64 years of age (4 of 9 patients); these subgroups constituted 23.5% and 52.9% of the cohort, respectively.
Estimated incidence rate was 13.8 patients and 5.7 deaths in ICUs per million residents in the Tel Aviv district. Again, the elderly subgroup was
